ClinicalTrials.gg
RecruitingNCT04408430MITRAL-IIUpdated Jan 13, 2026

The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

An interventional study of Transseptal ViMAC in Mitral Annular Calcification, Mitral Stenosis and Mitral Regurgitation, sponsored by Mayra Guerrero. Recruiting at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Mayra Guerrero · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Mitral Valve Stenosis with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Mitral Valve Stenosis · United States.

Started
2021
with 1 other
No phase
8 of 11
2 open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Mayra Guerrero

Among the 11 studies in Mitral Valve Stenosis with a site in United States, this one is one of 2 that started in 2021, is one of 8 with no phase, and was the 7th registered.

Mitral Valve Stenosis

63 studies on the registry are indexed under Mitral Valve Stenosis; 23 are open to participants now.

Browse Mitral Valve Stenosis studies →

Open to participants now

3 of the 11 studies in Mitral Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Mitral Valve Stenosis studies recruiting now, 12 (71%) set no upper age limit and none (0%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Mitral Valve Stenosis with a site in United States, or all of them as a file.
02

Study summary

A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.

Read the detailed description

STUDY OBJECTIVE

The purpose of this study is to establish the safety and effectiveness of the Edwards SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA (SAPIEN 3/Ultra/RESILIA) valves with Commander delivery system in patients with severe mitral annular calcification and symptomatic mitral valve dysfunction who are not candidates for standard mitral valve surgery.

STUDY DESIGN

A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 arms in this study: 1) "Transseptal (TS) Valve-in-MAC (ViMAC)" arm, 2) Natural History of Disease Registry (NHDR). Patients treated with medical treatment only (which will include patients who meet inclusion criteria but can't be treated with transseptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e. alcohol septal ablation, radiofrequency ablation).

Enrollment Enrollment will consist of 110 patients in the treatment arm (transseptal ViMAC) and up to 100 in the medically treated arm).

03

Conditions studied

  • Mitral Annular Calcification
  • Mitral Stenosis
  • Mitral Regurgitation
  • Mitral Valve Disease

Keywords

  • Transcatheter Mitral Valve Replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

All Candidates must meet the following criteria:

  1. - 18 years of age or older
  2. -Severe mitral annular calcification with symptomatic mitral valve dysfunction including severe mitral stenosis defined as mitral valve area (MVA) of ≤1.5 cm2, or ≥ moderate to severe mitral regurgitation, or mixed ≥ moderated stenosis and ≥ moderate regurgitation. For this study, the severity of mitral regurgitation will be graded according to the 2017 American Society of Echocardiography Guidelines: None, Trivial, Mild 1(+), Moderate 2(+), Moderate to severe 3(+), and severe 4(+).
  3. - Functional Class ≥II.
  4. The heart team agrees that valve implantation will likely benefit the patient.
  5. High or prohibitive risk for standard mitral valve surgery as determined by the heart team (at least one site cardiac surgeon must personally examine the subject to determine operative risk in patients presented for inclusion to ViMAC arm). NOTE: Patients not interested in mitral intervention or who are being considered for inclusion in the Natural History of Disease Registry are not required to be evaluated in person by a surgeon.)
  6. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written as approved by the Institutional Review Board (IRB) of the respective clinical site.
  7. The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years.

Exclusion Criteria for ViMAC subjects (does not apply to the Natural History of Disease Registry):

  1. - The heart team considers the patient is a surgical candidate.
  2. - Mitral annulus is not severely calcified.
  3. - Myocardial infarction requiring revascularization within 30 days from procedure.
  4. - untreated coronary artery disease requiring revascularization.
  5. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker is not exclusionary.
  6. Any patient with a balloon valvuloplasty (BMV) within 30 days of the procedure (unless BMV is a bridge to ViMAC procedure after a qualifying Echo).
  7. Severe symptomatic tricuspid regurgitation (hepatic dysfunction, ascites, edema not controlled with diuretics) requiring surgery.
  8. Leukopenia (WBC \< 3000 cell/mL), acute anemia ( \< 9 g/dL), Thrombocytopenia ( \< 50,000 cell/mL), history of coagulopathy or hypercoagulable state.
  9. Hypertrophic obstructive cardiomyopathy (HOCM) with mean LVOT gradient of ≥20 mm Hg at rest or ≥50 mmHg with Valsalva.
  10. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation.
  11. Need for emergency surgery for any reason.
  12. Severe left ventricular dysfunction with \< 20%.
  13. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
  14. Active upper GI bleeding within 90 days prior to procedure.
  15. A known or to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.
  16. Cardiac anatomy that would preclude appropriate delivery and deployment of an Edwards SAPIEN 3/Ultra/RESILIA valve in MAC via transseptal access, including but not limited to:

    • Native neo mitral annulus size \< 275 mm2 or > 810 mm2 as measured by CT scan.
    • Significant risk of LVOT obstruction or valve embolization as assessed by CT core lab
  17. Clinically (by neurologist) or neuroimaging confirmed stroke or (TIA) within 90 days of the procedure.
  18. Estimated \<12 months due to non-cardiac conditions.
  19. Expectation that patient will not improve despite treatment of mitral valve dysfunction.
  20. Active bacterial endocarditis within 180 days of procedure.
  21. - Severe right ventricular dysfunction as assessed by Echo core lab
  22. - Active infection requiring antibiotic therapy (subject may be a candidate after 2 weeks of antibiotic discontinuation.
  23. - Female who is pregnant or lactating.
  24. - Participating in another device study.
  25. - Aortic valve disease requiring intervention. If aortic valve intervention is required, the AVR procedure should be performed first and if the patient remains symptomatic after AVR, may be presented for consideration for inclusion in this trial.
  26. - Severe fixed pulmonary hypertension (PASP ≥70 mmHg and more than 2/3 of the systemic systolic blood pressure).
  27. - Severe requiring continuous home oxygen.
  28. - The patient refuses mitral valve intervention
  29. - Recent symptomatic COVID-19 infection with residual symptoms that may affect the outcomes of this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Transseptal ViMAC

    110 MAC patients treated with transseptal Valve-in-MAC.

    Device: Transseptal ViMAC

  • No intervention
    Registry of untreated patients

    100 MAC patients not eligible for transseptal ViMAC, treated with conservative management including medications.

Interventions

  • DeviceTransseptal ViMAC

    Transseptal TMVR using balloon-expandable aortic transcatheter valves.

    Also known as: ViMAC

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint: All Cause Morality and Hospitalization for Heart Failure

    A non-hierarchical composite of all-cause mortality and hospitalization for heart failure.

    Time frame: 1 year.

Secondary outcomes

  1. Secondary Effectiveness Endpoint

    • Stroke at 30 days and 1 year.

    Time frame: 1 year

  2. Secondary Effectiveness Endpoint

    • Change from baseline in New York Heart Association Class at 1 year.

    Time frame: 1 year.

  3. Secondary Effectiveness Endpoint

    • Change from baseline in distance walked measure by the 6 Minute Walk Test at 1 year.

    Time frame: 1 year.

  4. Secondary Effectiveness Endpoint

    • Change from baseline in quality-of-life measure by the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 1 year.

    Time frame: 1 year.

  5. Secondary Effectiveness Endpoint

    • Echocardiographic assessment of degree of mitral regurgitation (central and paravalvular) at 1 year.

    Time frame: 1 year.

  6. Secondary Effectiveness Endpoint

    • Significant mitral stenosis defined as mean mitral valve gradient by echo \> 10 mmHg at 1 year.

    Time frame: 1 year.

Other outcomes

  1. Additional Endpoint: Technical Success

    • Technical success at exit from the cath lab. Defined as: * Successful vascular access, delivery and retrieval of the transcatheter valve delivery system. * Deployment of a single valve. * Correct position of transcatheter valve in the mitral annulus. * Adequate performance of the prosthetic heart valve (MVA \> 1.5 cm2) without residual mitral regurgitation grade ≥2 (+). * No need for additional surgery or re-intervention (includes drainage of pericardial effusion). * The patient leaves the cath lab alive.

    Time frame: Immediately after the intervention procedure.

  2. Additional Endpoint: Procedural Success

    • Procedural Success at 30 days. Defined as: * Device success at 30 days. * No device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.

    Time frame: 30 days

  3. Additional Endpoint: Device Success

    Device success is defined as: * Stroke free survival with original valve in place. * No need for additional surgery or re-intervention related to the procedure, access or to the replacement valve. * Proper placement and intended function of the replacement valve, including * No migration, fracture, thrombosis, hemolysis or endocarditis. * No replacement valve stenosis (MV gradient \< 10 mmHg). * Replacement valve regurgitation \< 2 + (including central and paravalvular leak) and without associated hemolysis. * No increase in AI from baseline (more than 1 grade) and LVOT gradient \< 20 mmHg increase from baseline.

    Time frame: 30 days.

  4. Additional Efficacy Endpoint - NYHA Class at 30 days.

    • Change from baseline in NYHA Class at 30 days.

    Time frame: 30 days.

  5. Additional Efficacy Endpoint - Distance walked in 6 MWT at 30 days

    • Change from baseline in distance walked measure by the 6 MWT at 30 days.

    Time frame: 30 days.

  6. Additional Efficacy Endpoint - KCCQ at 30 days

    • Change from baseline in KCCQ at 30 days.

    Time frame: 30 days.

  7. Additional Efficacy Endpoint - MR severity at 30 days

    • Degree of mitral regurgitation (central and paravalvular) at 30 days.

    Time frame: 30 days

  8. Additional Safety Endpoint - Stroke at 30 days and 1 year.

    • Stroke at 30 days and 1 year.

    Time frame: 30 days and 1 year.

  9. Additional Safety Endpoint - Need for ASD Closure

    • Iatrogenic ASD causing RV failure or hypoxemia or need for ASD closure at discharge and 30 days.

    Time frame: 30 days.

  10. Additional Safety Endpoint - New LVOT Gradient

    • New mean LVOT gradient ≥ 20 mmHg, or ≥ 20 mmHg increase from baseline LVOT gradient at 30 days and 1 year.

    Time frame: 30 days and 1 year.

  11. Additional Efficacy Endpoint - Mitral Valve Reintervention

    • Mitral Valve reintervention at 30 days and 1 year.

    Time frame: 30 days and 1 year.

  12. Additional Safety Endpoint - Hospitalizations at 1 year

    • Number of hospitalizations at 1 year.

    Time frame: 1 year.

  13. Additional Efficacy Endpoint - Days Alive Out of the Hospital

    • Days alive out of hospital at 1 year from index procedure (ViMAC arm) or from assignment day (Natural History Registry).

    Time frame: 1 year.

  14. Additional Safety Endpoint - Hemolysis

    • Hemolysis at 30 days and 1 year.

    Time frame: 30 days and 1 year.

  15. Additional Safety Endpoint - Endocarditis

    • Endocarditis at 30 days and 1 year.

    Time frame: 30 days and 1 year.

  16. Additional Safety Endpoint - Blood Transfusion

    • Blood transfusion at 30 days and 1 year.

    Time frame: 30 days and 1 year.

  17. Additional Safety Endpoint - New Pacemaker Requirement

    • New pacemaker requirement at 30 days and 1 year.

    Time frame: 30 days and 1 year.

  18. Additional Safety Endpoint - New Aortic Valve Insufficiency

    • New aortic valve insufficiency at 30 days and 1 year.

    Time frame: 30 days and 1 year.

  19. Additional Safety Endpoint - Acute Kidney Injury

    • Acute kidney injury (MVARC) at 30 days and 1 year.

    Time frame: 30 days and 1 year.

07

Study locations

14 of 17 sites recruiting
08

References and documents

Publications

  • Russell HM, Guerrero ME, Salinger MH, Manzuk MA, Pursnani AK, Wang D, Nemeh H, Sakhuja R, Melnitchouk S, Pershad A, Fang HK, Said SM, Kauten J, Tang GHL, Aldea G, Feldman TE, Bapat VN, George IM. Open Atrial Transcatheter Mitral Valve Replacement in Patients With Mitral Annular Calcification. J Am Coll Cardiol. 2018 Sep 25;72(13):1437-1448. doi: 10.1016/j.jacc.2018.07.033. PubMed 30236304 ↗
  • Guerrero M, Wang DD, Himbert D, Urena M, Pursnani A, Kaddissi G, Iyer V, Salinger M, Chakravarty T, Greenbaum A, Makkar R, Vahanian A, Feldman T, O'Neill W. Short-term results of alcohol septal ablation as a bail-out strategy to treat severe left ventricular outflow tract obstruction after transcatheter mitral valve replacement in patients with severe mitral annular calcification. Catheter Cardiovasc Interv. 2017 Dec 1;90(7):1220-1226. doi: 10.1002/ccd.26975. Epub 2017 Mar 7. PubMed 28266162 ↗
  • Guerrero M, Wang DD, O'Neill W. Percutaneous alcohol septal ablation to acutely reduce left ventricular outflow tract obstruction induced by transcatheter mitral valve replacement. Catheter Cardiovasc Interv. 2016 Nov 15;88(6):E191-E197. doi: 10.1002/ccd.26649. Epub 2016 Jul 5. PubMed 27377756 ↗
  • Guerrero M, Urena M, Pursnani A, Wang DD, Vahanian A, O'Neill W, Feldman T, Himbert D. Balloon expandable transcatheter heart valves for native mitral valve disease with severe mitral annular calcification. J Cardiovasc Surg (Torino). 2016 Jun;57(3):401-9. PubMed 27094423 ↗
  • Guerrero M, Greenbaum A, O'Neill W. First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. Catheter Cardiovasc Interv. 2014 Jun 1;83(7):E287-91. doi: 10.1002/ccd.25441. Epub 2014 Mar 14. PubMed 24532349 ↗
  • Guerrero M, Urena M, Himbert D, Wang DD, Eleid M, Kodali S, George I, Chakravarty T, Mathur M, Holzhey D, Pershad A, Fang HK, O'Hair D, Jones N, Mahadevan VS, Dumonteil N, Rodes-Cabau J, Piazza N, Ferrari E, Ciaburri D, Nejjari M, DeLago A, Sorajja P, Zahr F, Rajagopal V, Whisenant B, Shah PB, Sinning JM, Witkowski A, Eltchaninoff H, Dvir D, Martin B, Attizzani GF, Gaia D, Nunes NSV, Fassa AA, Kerendi F, Pavlides G, Iyer V, Kaddissi G, Witzke C, Wudel J, Mishkel G, Raybuck B, Wang C, Waksman R, Palacios I, Cribier A, Webb J, Bapat V, Reisman M, Makkar R, Leon M, Rihal C, Vahanian A, O'Neill W, Feldman T. 1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification. J Am Coll Cardiol. 2018 May 1;71(17):1841-1853. doi: 10.1016/j.jacc.2018.02.054. PubMed 29699609 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2020
First posted
May 29, 2020
StartActual
Mar 8, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2030
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04408430
Lead sponsor
Mayra Guerrero
Responsible party
Mayra Guerrero (Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
May 29, 2020
Start date
Mar 8, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jan 13, 2026

Study contacts

Tatiana Kaptzan, Ph. D.
Contact
kaptzan.tatiana@mayo.edu
507-284-1610
Mayra Guerrero, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion